Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Somatropin biosimilar - Biopartners/LG Chem

Next Previous
Drug Profile

Somatropin biosimilar - Biopartners/LG Chem

Alternative Names: Declage; Eutrophine; Eutropin; Eutropin Plus; LB-03002; rhGH; Somatropin Biopartners; Somatropina Biopartners; SR-rhGH; Valtropin

Latest Information Update: 13 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LG Life Sciences
  • Developer Biopartners GmbH; LG Chem; LG Life Sciences; Merck KGaA
  • Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
  • Mechanism of Action Human growth hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Short stature; Somatotropin deficiency
  • Phase III Prader-Willi syndrome

Most Recent Events

  • 02 Jan 2020 LG Chem completes a phase I trial in Volunteers in South Korea (SC) (NCT04085224)
  • 16 Sep 2019 LG Chem plans a bioavailability phase I trial in Healthy volunteers (NCT04085224) (SC)
  • 03 Aug 2017 Phase-II development for Short stature (In children, Treatment-naive) is ongoing in South Korea (SC, Controlled release)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top